Profile data is unavailable for this security.
About the company
Hikma Pharmaceuticals PLC is a pharmaceutical company. The principal activities of the Company are the development, manufacture and marketing of a range of generic, branded and in-licensed pharmaceutical products. The Company operates through three segments: Injectables, Branded and Generics. The Injectables segment supplies hospitals across its markets with generic injectable products, supported by its manufacturing facilities in the United States, Europe and Middle East/North Africa (MENA). It is also engaged in the finished dosage form (FDF) business and has a manufacturing facility in Cleveland, Ohio. The Branded segment supplies branded generics and in-licensed patented products from its local manufacturing facilities to retail and hospital customers across the MENA region. The Generics segment supplies oral and other non-injectable generic and specialty products to the United States retail market, leveraging its manufacturing facility in Columbus, Ohio.
- Revenue in GBP (TTM)2.27bn
- Net income in GBP214.55m
- Incorporated2005
- Employees8.97k
- LocationHikma Pharmaceuticals PLC1 New Burlington PlaceLONDON W1S 2HRUnited KingdomGBR
- Phone+44 207 399 2760
- Fax+44 207 399 2761
- Websitehttps://www.hikma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Avidity Biosciences Inc | 7.98m | -190.03m | 4.01bn | 253.00 | -- | 4.09 | -- | 502.14 | -2.95 | -2.95 | 0.1231 | 11.17 | 0.0108 | -- | 17.92 | 41,893.28 | -25.78 | -31.61 | -27.61 | -34.45 | -- | -- | -2,381.82 | -1,540.50 | -- | -- | 0.00 | -- | 3.64 | 90.71 | -21.97 | -- | 143.89 | -- |
Kalbe Farma Tbk PT | 1.56bn | 150.35m | 4.01bn | 12.99k | 26.26 | 3.67 | 20.96 | 2.57 | 65.89 | 65.89 | 684.23 | 471.50 | 1.13 | 2.88 | 5.94 | 2,410,624,000.00 | 11.05 | 12.50 | 14.27 | 15.48 | 37.20 | 41.21 | 9.79 | 11.26 | 2.47 | -- | 0.0415 | 50.53 | 5.24 | 7.64 | -18.20 | 2.40 | -3.00 | 3.58 |
GlaxoSmithKline Pharmaceuticals Limited | 315.64m | 57.61m | 4.11bn | 3.21k | 71.44 | -- | 64.40 | 13.04 | 37.77 | 37.77 | 206.98 | -- | -- | -- | -- | 10,920,890.00 | -- | 11.01 | -- | 17.88 | 61.97 | 55.77 | 18.25 | 12.25 | -- | 490.08 | -- | 192.07 | 6.21 | 2.00 | -2.91 | 5.78 | -36.02 | 9.86 |
Guangzhou Baiyunshan Phrmcl Hldgs Co Ltd | 8.16bn | 404.08m | 4.12bn | 28.05k | 10.75 | 1.12 | -- | 0.5054 | 2.33 | 2.33 | 47.11 | 22.31 | 1.01 | 6.35 | 4.67 | 2,730,601.00 | 5.29 | 5.90 | 9.92 | 12.40 | 17.40 | 18.70 | 5.23 | 5.56 | 1.20 | -- | 0.3115 | 30.02 | 6.68 | 12.32 | 2.25 | 3.34 | 27.75 | 12.05 |
ALK-Abello A/S | 583.45m | 77.72m | 4.14bn | 2.81k | 58.69 | 8.17 | 36.99 | 7.10 | 3.09 | 3.09 | 22.91 | 22.22 | 0.7673 | 1.27 | 6.11 | 1,834,278.00 | 10.22 | 3.50 | 12.56 | 4.37 | 63.42 | 60.66 | 13.32 | 5.07 | 1.29 | 479.50 | 0.0934 | 0.00 | 6.94 | 10.60 | 45.07 | -- | 16.32 | -- |
Glenmark Pharmaceuticals Ltd | 1.08bn | -141.61m | 4.19bn | 14.99k | -- | -- | -- | 3.87 | -55.78 | -46.50 | 425.96 | -- | -- | -- | -- | 8,020,026.00 | -- | 1.02 | -- | 1.43 | 63.93 | 59.47 | -12.71 | 1.43 | -- | 1.78 | -- | 56.98 | 1.98 | 3.67 | -1,018.93 | -- | -5.89 | 4.56 |
Richter Gedeon Vegyeszeti Gyar Nyrt | 1.73bn | 488.38m | 4.28bn | 11.60k | 8.63 | 1.68 | 7.22 | 2.47 | 1,248.46 | 1,248.46 | 4,419.54 | 6,425.20 | 0.5959 | 1.36 | 3.77 | 69,931,480.00 | 16.92 | 11.64 | 19.01 | 13.28 | 68.64 | 58.18 | 28.40 | 18.93 | 2.03 | -- | 0.0454 | 39.94 | 0.2993 | 12.57 | -6.05 | 35.06 | 15.59 | 33.94 |
Hikma Pharmaceuticals Plc | 2.27bn | 214.55m | 4.36bn | 8.97k | 20.46 | 2.52 | 12.04 | 1.92 | 0.9597 | 0.9597 | 10.17 | 7.78 | 0.6374 | 1.77 | 3.38 | 253,280.60 | 6.13 | 8.19 | 8.47 | 11.30 | 47.40 | 50.29 | 9.61 | 13.77 | 0.9775 | 7.81 | 0.3568 | 36.71 | 14.22 | 6.73 | 1.06 | -7.59 | 7.97 | 14.03 |
Rohto Pharmaceutical Co Ltd | 1.47bn | 160.06m | 4.38bn | 7.26k | 26.50 | 3.11 | 20.98 | 2.98 | 132.56 | 132.56 | 1,215.22 | 1,129.95 | 0.7642 | 2.21 | 4.37 | 38,300,730.00 | 8.42 | 8.54 | 11.70 | 11.79 | 57.76 | 58.59 | 11.02 | 10.30 | 1.27 | -- | 0.1513 | 19.39 | 13.48 | 8.09 | 17.28 | 25.85 | 5.20 | 18.61 |
Beijing Tiantan Biological Products Corp | 567.76m | 135.17m | 4.40bn | 4.86k | 32.56 | 4.01 | -- | 7.75 | 0.6419 | 0.6419 | 2.70 | 5.22 | 0.3674 | 0.9077 | 222.80 | 1,097,335.00 | 11.86 | 11.71 | 17.11 | 16.50 | 53.54 | 49.39 | 32.28 | 27.71 | 3.23 | -- | 0.0074 | 16.67 | 21.57 | 12.06 | 25.99 | 16.85 | 29.67 | 38.97 |
Beijing Tongrentang Co Ltd | 1.90bn | 181.41m | 4.64bn | 16.78k | 25.56 | 3.27 | -- | 2.44 | 1.24 | 1.24 | 13.02 | 9.72 | 0.5916 | 1.14 | 12.61 | 1,064,742.00 | 8.41 | 8.20 | 16.20 | 16.17 | 45.25 | 46.59 | 14.22 | 13.33 | 1.90 | -- | 0.186 | 30.93 | 16.19 | 4.68 | 16.92 | 8.03 | -12.01 | 13.97 |
Siegfried Holding AG | 1.14bn | 113.85m | 4.67bn | 3.80k | 39.04 | 5.52 | 24.54 | 4.10 | 29.87 | 29.87 | 299.09 | 211.39 | 0.7046 | 2.00 | 3.80 | 326,556.30 | 7.06 | 6.51 | 8.64 | 7.98 | 25.87 | 23.24 | 10.03 | 9.06 | 1.40 | 14.34 | 0.3217 | 15.26 | 3.41 | 9.87 | -28.16 | 18.34 | 17.95 | 6.72 |
Holder | Shares | % Held |
---|---|---|
Wellington Management Co. LLPas of 31 Dec 2023 | 11.56m | 5.21% |
JPMorgan International Bank Ltd.as of 03 Sep 2024 | 10.75m | 4.84% |
Capital Research & Management Co. (World Investors)as of 03 Sep 2024 | 7.07m | 3.19% |
BlackRock Advisors (UK) Ltd.as of 31 Dec 2023 | 6.15m | 2.77% |
Mawer Investment Management Ltd.as of 31 Dec 2023 | 4.66m | 2.10% |
The Vanguard Group, Inc.as of 03 Sep 2024 | 4.22m | 1.90% |
Royal London Asset Management Ltd.as of 03 Sep 2024 | 3.15m | 1.42% |
Polar Capital LLPas of 28 Jun 2024 | 3.10m | 1.40% |
Threadneedle Asset Management Ltd.as of 30 Jun 2024 | 3.10m | 1.40% |
Norges Bank Investment Managementas of 03 Sep 2024 | 2.62m | 1.18% |